Publishers announce changes, broader focus for DDNEWS
By Bruce Poorman, DDNEWS Publisher
and Laurence Doyle, DDNEWS Associate Publisher
As you pick up our latest issue, you can see there is something new about ddn. Our front cover this month shows a change, but it is more about ddn continuing to evolve with the news of the changing technology in pharma, biotech and life-science research.
In 2005, we launched Drug Discovery News. That was during a time when there were several other publications with discovery and genomics-related titles, and we were positioned as a business news publication covering the pharmaceutical industry. As the news and market evolved, in 2007 we updated our title to the acronym ddn to better identify our growing coverage beyond just discovery to include the development, diagnostic and drug delivery stages of the pipeline.
Now in our ninth year, with 12 news vehicles, our coverage continues to evolve further up the pipeline, and we are bringing you not only the news of mergers, acquisitions, regulations and collaborations, but also providing breaking stories with broader perspectives about technologies and market developments that impact our readers from the bench to the boardroom in pharma, biotech and life science.
The most visual change is our new front cover design. Our new logo continues to be anchored to our ddn branding, but emphasizes our unique position in the market as delivering NEWS. News is what defines and sets us apart from other publications as we follow pharma, biotech and life-science research. With our new design comes a new, easy-to-remember URL address: www.DDN-News.com.
Our readership is involved with basic and applied research throughout the pipeline as demonstrated by a recent survey that confirms ddn as being "the bridge from discovery to clinical trials." This study conducted over the ddn subscriber list showed that 58 percent of researchers were involved in discovery and development; 24 percent are involved in diagnostics and clinical trials and 11 percent are involved in QA/QC in manufacturing.
With a new focus showing a balance between business and technology, you will find stories of broader interest that ask important questions, as in some of the stories you will read this month: With pharma companies clinging to the patent cliff, how important will R&D collaborations become? What are some of the unique challenges facing clinical trials in oncology? Why are some important diagnostic developments not receiving the attention and credit they deserve?
To continue our broader coverage, our July issue will include the first of a three-part feature on trends in stem cell research. The July through September issues of DDNEWS will examine the pluripotential possibilities inherent in stem cells, whether as the bases of technologies aimed at improving our understanding of human health or as direct therapeutic mechanisms to fight disease. July's special feature will tackle the arduous challenges of identifying and maintaining stem cell stocks as parts of vast biorepositories.
In August, we will examine the use of stem cells as research tools both as a passive template upon which new therapeutics are developed, and as active participants in the search for a broader understanding of pathophysiology. September's issue will conclude the series with a discussion of the roles that stem cells are playing as treatments for human disease as either unmodified replacements for defective biological systems or tweaked agents tackling difficult medical challenges.
As much as this June issue signifies change, it also marks the evolution of our news coverage through the pipeline of drug discovery, development, diagnostics and delivery. We are still ddn and our mission remains the same: to deliver the balanced news of pharma, biotech and life-science business and technology. We are DDNEWS.